Geron Investors Ink $24M Deal Over Cancer Study Results

By Donald Morrison · September 6, 2022, 6:25 PM EDT

Geron Corp. investors have reached a $24 million settlement resolving their claims that the biotechnology company and its chief executive officer hid negative results of a clinical trial for a blood...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Tollen v. Geron Corporation et al

Case Number

3:20-cv-00547

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

January 23, 2020